top of page

Process
Technology
Partnerships
Case Studies & Pipeline
News
Contact
About
More

Use tab to navigate through the menu items.

Dark background with hint of blue abstract data.jpg

News

Subscribe to Newsletter

Qubigen to Attend Discovery on Target 2025 in Boston

Qubigen to Attend Discovery on Target 2025 in Boston

Qubigen to Attend Discovery on Target 2025 in Boston

Qubigen is pleased to announce that Matthew Oristano, Strategic Advisor and Investor in Qubigen, will be attending Discovery on Target ...

Sep 16, 20251 min read

Qubigen Signs Agreement with SyzOnc to Apply AI-Driven Drug Development to Promising Oncology Targets

Qubigen Signs Agreement with SyzOnc to Apply AI-Driven Drug Development to Promising Oncology Targets

Qubigen Signs Agreement with SyzOnc to Apply AI-Driven Drug Development to Promising Oncology Targets

Qubigen is pleased to announce the signing of an agreement with SyzOnc , an oncology-focused biotech company advancing novel approaches...

Sep 15, 20252 min read

Qubigen Signs Data Access Agreement with Flinders University

Qubigen Signs Data Access Agreement with Flinders University

Qubigen Signs Data Access Agreement with Flinders University

Qubigen is pleased to announce the signing of a Data Access Master Agreement with Flinders University , establishing a framework for...

Sep 4, 20252 min read

enquiries@qubigen.com

Bio21 Institute

30 Flemington Road

Parkville VIC 3052

Australia

Accelerate drug design
without exposing secrets

Connect with Us

© 2025 Qubigen. All rights reserved.

bottom of page